Search

Displaying results 2651 - 2660 of 10000 in total
  1. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    [A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. … [L46287] It was fully approved by the EMA in May 2023.[L46596]

  2. Drug

    Synthetic Conjugated Estrogens, B

    go.drugbank.com/drugs/DB09318
    Approved

    Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. … Pharmacologic estrogen products are available in a variety of formats.

  3. Drug

    Dexmethylphenidate

    go.drugbank.com/drugs/DB06701
    ApprovedInvestigational

    Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002[A177181]. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193].

  4. Drug

    Gallium Ga-68 gozetotide

    go.drugbank.com/drugs/DB16019
    ApprovedInvestigational

    [L27006] On December 1, 2020, Ga-68 PSMA-11 was approved by the FDA as the first molecular-targeted drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) … positive lesions in men with prostate cancer.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Synthetic Conjugated Estrogens, A

    go.drugbank.com/drugs/DB09317
    Approved

    Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. … Pharmacologic estrogen products are available in a variety of formats.

  6. Drug

    Naldemedine

    go.drugbank.com/drugs/DB11691
    ApprovedInvestigational

    Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. … It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier.

  7. Drug

    Alcaftadine

    go.drugbank.com/drugs/DB06766
    Approved

    This drug was approved in July 2010.

  8. Drug

    Imdevimab

    go.drugbank.com/drugs/DB15940
    ApprovedInvestigational

    [A221495] On November 21, 2020, the FDA authorized emergency approval of REGN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. … [L23524] In November 2021, the same indication was approved by the EMA.

  9. Drug

    Irofulven

    go.drugbank.com/drugs/DB05786
    Investigational

    Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe. … MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis.

  10. Drug

    Talazoparib

    go.drugbank.com/drugs/DB11760
    ApprovedInvestigational

    [L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020. … [L47301] Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306]

    Products: TALZENNA CAPSULE 1MG, Talzenna 1mg Hard Capsules